Reed Elsevier Shares Slightly Overvalued

Reed's 2H and FY results reaffirm our view that the company has competitive advantages despite some near-term headwinds

Michael Corty, CFA 21 February, 2011 | 3:38PM
Facebook Twitter LinkedIn

After reviewing Reed Elsevier's (REL) solid second-half and full-year results, we reaffirm our view that the company has competitive advantages despite some near-term headwinds. Full-year sales growth of 2%, excluding dispositions in the smaller Reed Business Information segment, was on par with our expectations and we're comfortable with our 3% sales growth estimate for 2011.

Reed Elsevier's two major segments with the greatest competitive positioning—Elsevier and LexisNexis—both posted solid results given headwinds facing the businesses. Elsevier, which includes its science, technology and health sciences publishing units, posted 2% sales growth. A difficult academic budget environment was not a surprise, and kept a lid on growth. However, we're expecting slight improvement in 2011. The LexisNexis segment achieved sales growth of 1% in 2010, with risk solutions outpacing legal information growth. The company's legal publishing segment continues to be a lagging indicator, as law firm hiring is still in recovery mode. Also, competition from Thomson continues to serve as a headwind for Reed Elsevier. Overall adjusted operating margins of 26% were flat with the prior year, with Elsevier margin improvement offsetting lower profitability for LexisNexis. We think the Reed Elsevier's shares are slightly overvalued at the current price.

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Facebook Twitter LinkedIn

About Author

Michael Corty, CFA  Michael Corty, CFA, is an equity analyst with Morningstar.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures